Compare · BDX vs PSTV
BDX vs PSTV
Side-by-side comparison of Becton Dickinson and Company (BDX) and PLUS THERAPEUTICS Inc. (PSTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PSTV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $44.07B, about 1641.6x PSTV ($26.8M).
- Over the past year, BDX is down 12.5% and PSTV is down 61.0% - BDX leads by 48.5 points.
- PSTV has been more active in the news (12 items in the past 4 weeks vs 8 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 3 for PSTV).
- Company
- Becton Dickinson and Company
- PLUS THERAPEUTICS Inc.
- Price
- $158.16-1.07%
- $3.70-4.15%
- Market cap
- $44.07B
- $26.8M
- 1M return
- +8.93%
- -19.91%
- 1Y return
- -12.54%
- -61.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 3
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
PLUS THERAPEUTICS Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest PSTV
- Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
- Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
- Director Andrews Ronald Asbury converted options into 922 shares (SEC Form 4)
- Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 43% to 9,941 units (SEC Form 4)
- Director Hawkins Richard J converted options into 922 shares, increasing direct ownership by 152% to 1,529 units (SEC Form 4)
- Director Van Es-Johansson An converted options into 922 shares (SEC Form 4)
- Director Clowes Howard converted options into 922 shares, increasing direct ownership by 87% to 1,981 units (SEC Form 4)
- Chief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 59% to 44,483 units (SEC Form 4)
- Director Guse Kyle converted options into 922 shares (SEC Form 4)
- Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding